Myomo, Inc. (MYO)
AMEXHealth CareMedical - DevicesSnapshot 2026-09-04
$1.44+2.86%
Close 2026-09-04 · 1-day change
AMEXHealth CareMedical - DevicesSnapshot 2026-09-04
Broken: Primary pillar broken — Operating loss improves toward less negative than -$3.16M: metric not reported.
Myomo aims for $43M to $46M revenue in 2026. Revenue in Q1 was $10.11M, near guidance. Operating loss improved from -$4.59M to -$3.16M in recent quarters. The company is working to reduce losses and grow sales.
Myomo is still losing money and cut revenue guidance. Sales growth may slow below 17%. Operating losses remain large and could worsen. The recent selloff shows investor doubts about recovery.
The market expects about 17% revenue growth. Our fair value is near $4.29, reflecting this growth. The stock is down 25% from highs, pricing in risk from losses and guidance cuts.
Breaks if: Operating loss worsens beyond -$3.16 million
Breaks if: Q2 revenue falls below $10.3 million
Breaks if: Revenue falls below $43 million in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround story in the healthcare sector. The company is currently loss-making but is making strides towards achieving revenue targets and shifting to recurring revenue sources.
The market seems to assume a justified valuation, as MYO is priced cheaply compared to its peers. However, there is a significant expectations gap, indicating that the market may not fully recognize the potential for growth.
Management is on track to meet its revenue goals, with recent performance showing positive growth trends. However, the company operates in a high-risk environment, which could impact its ability to sustain this momentum.
The long-term thesis hinges on the company's ability to maintain revenue growth and manage expenses effectively. Additionally, external factors such as sector performance and economic conditions will play a critical role in shaping MYO's trajectory.
The most important moves since the prior daily snapshot.
Signal changed from 'mild_favorable' to 'mixed'.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Management aims to achieve full year 2026 revenue in the range of $43 million to $46 million.
Overall, MYO is positioned for potential growth, but faces significant risks that could affect its performance. Not investment advice.